Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)

NCT05509530 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

OTHER: anti-BCMA/GPRC5D CAR-T CELL

Sponsor

Xuzhou Medical University